About Ordaos
Ordaos is a company based in New York (United States) founded in 2019 by Ulo Palm and Ziwei Liang. Ordaos has raised $21.49 million across 6 funding rounds from investors including NuFund, VTC Ventures and Route 66 Ventures. Ordaos offers products and services including miniPRO™ and Ordaōs Design Engine. Ordaos operates in a competitive market with competitors including AbSci, LabGenius, immunitoAI, Enpicom and Alkira Bio, among others.
- Headquarter New York, United States
- Founders Ulo Palm, Ziwei Liang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ordaos, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$21.49 M (USD)
in 6 rounds
-
Latest Funding Round
$337.71 K (USD), Seed
Feb 13, 2025
-
Investors
NuFund
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ordaos
Ordaos offers a comprehensive portfolio of products and services, including miniPRO™ and Ordaōs Design Engine.
De novo designed mini-proteins for targeted drug discovery applications.
Generative AI tool for creating and optimizing protein sequences.
People of Ordaos
Unlock access to complete
Funding Insights of Ordaos
Ordaos has successfully raised a total of $21.49M across 6 strategic funding rounds. The most recent funding activity was a Seed round of $337.71 thousand completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ordaos
Ordaos has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include NuFund, VTC Ventures and Route 66 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Technology sectors are invested in by NuFund venture capital firm.
|
Locked | Locked | Locked | |
|
Early stage investments are made by VTC Ventures.
|
Locked | Locked | Locked | |
|
Early, growth & late stage VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Ordaos
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ordaos
Investment portfolio details for Ordaos
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ordaos
Detailed financials for Ordaos
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ordaos Comparisons
Peer comparison for Ordaos
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ordaos
Ordaos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AbSci, LabGenius, immunitoAI, Enpicom and Alkira Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
AI-driven platform for discovering and optimizing therapeutic antibodies for treatments.
|
|
| Locked | Locked | Locked |
An AI-based platform for antibody discovery and therapeutics is developed.
|
|
| Locked | Locked | Locked |
Developer of bioinformatics platform integrating data, automation, and AI for biologics
|
|
| Locked | Locked | Locked |
Therapeutic antibodies targeting complex membrane proteins are developed.
|
Detailed competitors of Ordaos
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ordaos
Complete news archive for Ordaos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ordaos
Ordaos was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Ordaos is headquartered in New York, United States. It is registered at New York, New York, United States.
David Longo is the current CEO of Ordaos.
Ordaos is a funded company, having raised a total of $21.49M across 6 funding rounds to date.
Ordaos was founded in 2019 and is headquartered in New York, United States. An AI accelerator is offered by the company within the biomedical sector, focusing on drug discovery. The platform delivers an AI-driven pipeline that supports researchers in developing novel immunotherapies targeted at oncology and chronic inflammatory diseases. Operations emphasize efficient research workflows for therapeutic advancements.
Ordaos's top competitors include AbSci, immunitoAI and Enpicom.
Ordaos offers miniPRO™ and Ordaōs Design Engine.
Ordaos has 6 investors. Key investors include NuFund, VTC Ventures, Route 66 Ventures, Banyan Pacific Capital, and Citta Capital.